JP7485604B2 - メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法 - Google Patents

メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法 Download PDF

Info

Publication number
JP7485604B2
JP7485604B2 JP2020539735A JP2020539735A JP7485604B2 JP 7485604 B2 JP7485604 B2 JP 7485604B2 JP 2020539735 A JP2020539735 A JP 2020539735A JP 2020539735 A JP2020539735 A JP 2020539735A JP 7485604 B2 JP7485604 B2 JP 7485604B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
group
fold
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020539735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511320A (ja
Inventor
ビー．ウェイナー デイビッド
デュペレット エリザベス
Original Assignee
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー filed Critical ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー
Publication of JP2021511320A publication Critical patent/JP2021511320A/ja
Priority to JP2024074955A priority Critical patent/JP2024096334A/ja
Application granted granted Critical
Publication of JP7485604B2 publication Critical patent/JP7485604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020539735A 2018-01-19 2019-01-18 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法 Active JP7485604B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074955A JP2024096334A (ja) 2018-01-19 2024-05-02 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619161P 2018-01-19 2018-01-19
US62/619,161 2018-01-19
PCT/US2019/014171 WO2019143921A2 (en) 2018-01-19 2019-01-18 Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074955A Division JP2024096334A (ja) 2018-01-19 2024-05-02 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2021511320A JP2021511320A (ja) 2021-05-06
JP7485604B2 true JP7485604B2 (ja) 2024-05-16

Family

ID=67302504

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020539735A Active JP7485604B2 (ja) 2018-01-19 2019-01-18 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法
JP2024074955A Pending JP2024096334A (ja) 2018-01-19 2024-05-02 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074955A Pending JP2024096334A (ja) 2018-01-19 2024-05-02 メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法

Country Status (11)

Country Link
US (2) US11524065B2 (enExample)
EP (1) EP3740226A4 (enExample)
JP (2) JP7485604B2 (enExample)
KR (1) KR20200110678A (enExample)
CN (2) CN120514835A (enExample)
AU (2) AU2019210063B2 (enExample)
BR (1) BR112020014632A2 (enExample)
CA (1) CA3088374A1 (enExample)
EA (1) EA202091732A1 (enExample)
MX (1) MX2020007676A (enExample)
WO (1) WO2019143921A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028165A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP3101134A1 (en) * 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) * 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine
AU2019210063B2 (en) * 2018-01-19 2025-03-06 The Wistar Institute Of Anatomy And Biology Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cell & Bioscience, 2013, Vol.3, Article No.29, pp.1-8
Human Vaccines & Immunotherapeutics, 2015, Vol.11, No.8, pp.1945-1953
Int. J. Cancer, 2015, Vol.136, pp.E290-E300
J. Biol. Chem, 2011, Vol.286, No.19, pp.17079-17090
J. Virology, 2015, Vol.89, No.8, pp.4191-4200
Trends Mol. Med., 2014, Vol.20, No.11, pp.604-613

Also Published As

Publication number Publication date
US20200345830A1 (en) 2020-11-05
AU2025204247A1 (en) 2025-06-26
WO2019143921A3 (en) 2020-04-09
US20230201328A1 (en) 2023-06-29
CN111801111B (zh) 2025-06-10
CN120514835A (zh) 2025-08-22
KR20200110678A (ko) 2020-09-24
BR112020014632A2 (pt) 2021-01-05
CA3088374A1 (en) 2019-07-25
MX2020007676A (es) 2020-11-12
CN111801111A (zh) 2020-10-20
AU2019210063B2 (en) 2025-03-06
JP2024096334A (ja) 2024-07-12
EP3740226A2 (en) 2020-11-25
WO2019143921A2 (en) 2019-07-25
JP2021511320A (ja) 2021-05-06
US11524065B2 (en) 2022-12-13
EP3740226A4 (en) 2021-10-13
EA202091732A1 (ru) 2020-09-10
AU2019210063A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP2024150611A (ja) Ｗｔ１ワクチン
US20220354945A1 (en) Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2024096334A (ja) メルケル細胞ポリオーマウイルスのラージおよびスモールｔ抗原、それから作製される核酸構築物およびワクチン、ならびにそれを使用する方法
US12296001B2 (en) DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)
US12390521B2 (en) Canine distemper vaccines and methods of treatment using the same
US12268735B2 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2019532935A (ja) 線維芽細胞活性化タンパク質を標的にする最適化された合成コンセンサス免疫原性組成物
US20250276051A1 (en) Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
US12194000B2 (en) Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)
US11865166B2 (en) Nucleic acid encoding optimized immunogenic peptide that targets follicle stimulating hormone receptor
HK40038957A (en) Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
EA045600B1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240502

R150 Certificate of patent or registration of utility model

Ref document number: 7485604

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150